MedPath

Self-sampling for Non-participants in an Organised Cervical Cancer Screening Programme

Not Applicable
Completed
Conditions
Cervical Cancer
Interventions
Behavioral: HPV self-sampling kit mailed directly
Behavioral: HPV self-sampling kit on demand
Behavioral: Second reminder
Registration Number
NCT02680262
Lead Sponsor
University of Aarhus
Brief Summary

The trial will evaluate the effect on participation in organised screening programme of a human papilloma virus (HPV) self-sampling kit directly mailed home or mailed on demand compared with the standard second reminder for regular screening.

Detailed Description

The CHOice trial is a parallel randomised controlled, open label trial. Participants will be equally randomised into three arms: 1) Directly mailed a second reminder including a HPV self-sampling kit; 2) Mailed a second reminder offering a HPV self-sampling kit, to be ordered by e-mail, by text message, by phone, or by website; and 3) Mailed a second reminder for a conventional practitioner-collected sample (control group).

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
9327
Inclusion Criteria
  • Women resident in the Central Denmark Region who have not participate in cervical cancer screening after an invitation and one reminder
Read More
Exclusion Criteria
  • Women younger than 30 years are not included due to the lower specificity of HPV DNA tests in younger women
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention group 1HPV self-sampling kit mailed directlyHPV self-sampling kit mailed directly
Intervention group 2HPV self-sampling kit on demandHPV self-sampling kit on demand
Intervention group 3Second remindersecond reminder
Primary Outcome Measures
NameTimeMethod
Women who participate by returning a HPV self-sampling kit or having a practitioner-collected sample in the intervention groups compared to the proportion of women who have a practitioner-collected sample in the control group at 90 days after mail out.90 days

Primary outcome will be the proportion of women who participate by returning a HPV self-sampling kit or having a practitioner-collected sample in the intervention groups compared to the proportion of women who have a practitioner-collected sample in the control group at 90 days after mail out.

Secondary Outcome Measures
NameTimeMethod
Women with a positive HPV self-collected sample who attend follow-up testing at 30, 60 or 90 days after mail out.30,60 or 90 days

Secondary outcome will be the proportion of women with a positive HPV self-collected sample who attend follow-up testing at 30, 60 or 90 days after mail out of results

Trial Locations

Locations (1)

Mette Tranberg Nielsen

🇩🇰

Randers, Randers NØ, Denmark

© Copyright 2025. All Rights Reserved by MedPath